Regeneron to defend against DOJ complaint on drug-price manipulation
Send a link to a friend
[April 16, 2024]
(Reuters) -Regeneron Pharmaceuticals said on Monday it seeks to
defend against U.S. Department of Justice's complaint that alleged the
company misreported the average sales price of its macular degeneration
drug Eylea.
"Reimbursing credit card service fees to distributors is not a price
concession and does not affect EYLEA's price," Regeneron said in a
statement, adding that it considered the complaint to be "meritless".
The DOJ last week, in a complaint filed in federal court in Boston,
alleged the drugmaker failed for years to report how it paid hundreds of
millions of dollars to subsidize Eylea purchases by reimbursing drug
distributors for credit-card processing fees.
The drug, which the Tarrytown, New York-based company began marketing in
2011, is approved by the U.S. Food and Drug Administration for treating
conditions including wet age-related macular degeneration, which impairs
vision.
[to top of second column]
|
![](../images/041624PIX/health94.jpg)
The Regeneron Pharmaceuticals company logo is seen on a building at
the company's Westchester campus in Tarrytown, New York, U.S.
September 17, 2020. REUTERS/Brendan McDermid/File Photo
![](http://archives.lincolndailynews.com/2024/Apr/16/images/ads/current/peasley_lda_051513.png) (Reporting by Kanjyik Ghosh in
Bengaluru; Editing by Shilpi Majumdar and Rashmi Aich)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |